Gastroenterology

This group also had a longer time to event of first IBD-related hospitalization and primary and secondary IBD-related surgery in patients without a history of IBD-related surgery at baseline.

There were no differences found in the total thickness of other esophageal regions, dysphagia score, endoscopic appearance, and eosinophil count over time.

Individuals with comorbid asthma, allergic rhinitis, and oral allergy syndrome had higher rates of eosinophilic esophagitis.

The results show methotrexate exposure time and cumulative doses were not predictors for fibrosis, but alcohol was a predictor.

The most common invasive fungal infection was histoplasmosis and the risk of invasive fungal infections was more than double in patients treated with corticosteroids than it was for patients treated with anti-TNFs.

The results show a placebo-controlled trial is warranted in the future.

Patients who were PCR positive or likely colonized in the two-step era were 20 times less likely to be associated with treatment for CDI, without adversely impacting patient outcomes.

FMT was cost-effective compared to vancomycin in both the general CDI population, as well as the subset of patients with IBD. However, it was less cost-effective in compared to fidaxomicin.

There was a 2.35-fold risk increase in PCCRC in the lowest ADR group compared to the highest.

There were no serious adverse events in the group of patients treated with colesevelam.

From new ACG GERD guidelines to the efficacy of colonoscopies, our latest issue addresses topics changing practice and stirring conversation.

A review of changes to clinical, dietary and screening strategies for patients with GERD.

A northern Europe-based trial highlights the potential impact of streamlined and community-supported colonoscopy screening for cancer.

A recent randomized controlled trial showed the limitations of either option, despite being a cornerstone of care.

Analysis from a multicenter, randomized, double-blind, parallel group study comparing the drugs as induction and maintenance therapies in biologic-naïve patients.

Only 2 of the households sampled featured an owner and pet who both tested positive for C. difficile.

The treatment was well-tolerated, with all serious treatment emergent adverse events considered not related to the treatment.

The results show the ADR in the early session of the unassisted group was significantly higher compared to those in the late session.

Sofosbuvir-based regimens were the most commonly prescribed therapies to treat hepatitis C virus in Asia, Africa, and the Commonwealth of Independent States.

The results show adherence to 6 quality indicators was linked to improvements in the post-intervention cohort with significant increases in C difficile testing, CRP testing, testing for latent tuberculosis, thromboprophylaxis, adequate corticosteroids prescription, and limitation of narcotics prescribed.

The results also show a decrease in antibiotic use, hospital length of stay, and overall cost to the patient.

Thus far, the phase 2 data on CP101 was generally positive for the treatment of recurrent C difficile infections.

While 20% of the patient population had a Fib-4 index greater than 1.3, including 1 case of a Fib-4 index greater than 2.67, the investigators did not identify a significant increase in Fib-4 index in patients with fatty liver compared to those who did not develop fatty liver.

The rate of adverse events was lower in the combination group than it was in patients in the guselkumab or golimumab monotherapy groups at week 50.

The majority of healthcare workers included in the study were immune to both measles and rubella.